| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6091269 | Clinical Gastroenterology and Hepatology | 2015 | 33 Pages |
Abstract
Compared with studies from referral centers, population-based studies of IBD patients show a lower but significantly increased risk of lymphoma among patients taking thiopurines. The increased risk does not appear to persist after discontinuation of therapy. Patients over 50 have the highest absolute risk of lymphoma per year on thiopurines, while men under 35 may also be a high risk group. More study is needed to precisely understand groups highest at risk. The risks of lymphoma and potential benefits of therapy should be considered for all patients with IBD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
David S. Kotlyar, James D. Lewis, Laurent Beaugerie, Ann Tierney, Colleen M. Brensinger, Javier P. Gisbert, Edward V. Jr., Laurent Peyrin-Biroulet, Wojciech C. Blonski, Manuel Van Domselaar, Maria Chaparro, Sandipani Sandilya, Meenakshi Bewtra,